Novartis receives approval for Cosentyx label update in Europe to include dosing flexibility in psoriatic arthritis
- New Cosentyx (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1]
- Cosentyx inhibits progression of joint damage in psoriatic arthritis (PsA) and shows rapid and sustained resolution of enthesitis, by inhibiting IL-17A[2]-[4]
- PsA is a chronic, progressive and irreversible disease leading to pain, fatigue, activity impairment and significant mobility loss due to structural damage[5]
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.com